NCT00217386View on ClinicalTrials.gov

Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

December 31, 2007

Conditions
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Interventions
BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

etanercept

Trial Locations (4)

98362

Olympic Medical Center, Port Angeles

98225-1898

St. Joseph Cancer Center, Bellingham

98109-1023

Seattle Cancer Care Alliance, Seattle

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00217386 - Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter